Effect of Bronchofiberscopic Lavage with Budesonide Suspension on Refractory Mycoplasma Pneumoniae Pneumonia

Overview

Journal Pak J Med Sci

Specialty General Medicine

Date 2022 May 31

PMID 35634588

Authors

Ya Li

Wei Yang

Xin Wu

Xiaohua Gou

Affiliations

Soon will be listed here.

Abstract

Objectives: To investigate the clinical efficacy of budesonide suspension through bronchofiberscopic lavage in the treatment of refractory mycoplasma pneumoniae pneumonia.(RMPP).

Methods: A total of 108 children with refractory mycoplasma pneumoniae pneumonia from June 2018 to October 2020 were randomly divided into two groups: the study group and the control group, with 54 cases in each group. Children in the control group were treated with anti-infective, antitussive, antipyretic routine symptomatic treatment and nebulization of budesonide suspension, while children in the study group were treated with bronchofiberscopic lavage with Budesonide suspension along with standard treatment as in control group. The clinical efficacy, changes in blood gas analysis indexes, levels of inflammatory mediators, time for improvement of clinical symptoms and the incidence of adverse reactions were compared between the two groups.

Results: The efficacy of treatment in the study group was 85.19%, which was higher than 66.67% in the control group (P<0.05). The antipyretic time, antitussive time, lung rales disappearance time and length of hospital stay in the study group were shorter than those in the control group (P<0.05). Moreover, the levels of arterial oxygen partial pressure (PaO) in the study group were higher than those in the control group, while the levels of partial pressure of carbon dioxide (PaCO) and arterial oxygen saturation (SaO) in the study group were lower than those in the control group (P<0.05). The levels of inflammatory mediators interleukin-6 (IL-6), interleukin-4 (IL-4), and interferon-γ (IFN-γ) in the study group were lower than those in the control group (P<0.05), and no significant difference was found in the comparison of the incidence of adverse reactions between the two groups (P>0.05).

Conclusions: Budesonide suspension combined with bronchofiberscopic lavage with Budesonide suspension is a safe treatment regimen that can significantly improve the clinical outcome in children with RMPP. With such a combined treatment regimen, the clinical symptoms of children can be ameliorated, the ventilation function can be enhanced, and the level of inflammatory mediators will be reduced.

Citing Articles

Predictive value of plasma sB7-H3 and YKL-40 in pediatric refractory Mycoplasma pneumoniae pneumonia.

Zhao Q, Ji S, Jiang H, Lu D, Qian L, Zhang J Open Med (Wars). 2025; 20(1):20241114.

PMID: 39822987 PMC: 11737367. DOI: 10.1515/med-2024-1114.

Clinical value of Vitamin-D combined with budesonide/formoterol and theophylline sodium glycinate sustained-release tablets in the treatment of chronic obstructive pulmonary disease patients.

Ni X, Zhou S, Wang C, Chen S, Hu J, Zhang S Pak J Med Sci. 2024; 40(7):1391-1396.

PMID: 39092061 PMC: 11255827. DOI: 10.12669/pjms.40.7.9495.

Effect of different doses of Budesonide combined with Tiotropium bromide inhalation on elderly patients with chronic obstructive pulmonary disease.

Yu J, Ni J, Chen X, Fang Y, Fu S Pak J Med Sci. 2024; 40(7):1338-1344.

PMID: 39092049 PMC: 11255806. DOI: 10.12669/pjms.40.7.9209.

Meta-analysis of combined azithromycin and inhaled budesonide treatment for Chinese pediatric patients with mycoplasma pneumonia.

Zhao J, Pan X, Shao P Medicine (Baltimore). 2024; 103(24):e38332.

PMID: 38875395 PMC: 11175896. DOI: 10.1097/MD.0000000000038332.

The effect of budesonide combined with bifidobacteria and lactobacilli on lung function and gut microbiota of patients with chronic obstructive pulmonary disease.

Liu Y, Ye F, Ma L Pak J Med Sci. 2024; 40(4):695-700.

PMID: 38545026 PMC: 10963960. DOI: 10.12669/pjms.40.4.8514.

References

Dorinsky P, DePetrillo P, DeAngelis K, Trivedi R, Darken P, Gillen M . Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults. Clin Ther. 2020; 42(4):634-648. DOI: 10.1016/j.clinthera.2020.02.012. View

Venge P, Eriksson S, Pauksen K . Blood biomarker algorithms for the diagnosis of mycoplasma pneumoniae respiratory infections. J Immunol Methods. 2020; 489:112908. DOI: 10.1016/j.jim.2020.112908. View

Li H, Zhao X, Zha Y, Du F, Liu J, Sun L . miR‑146a‑5p suppresses ATP‑binding cassette subfamily G member 1 dysregulation in patients with refractory Mycoplasma pneumoniae via interleukin 1 receptor‑associated kinase 1 downregulation. Int J Mol Med. 2019; 44(6):2003-2014. PMC: 6844629. DOI: 10.3892/ijmm.2019.4380. View

Lee E, Lee Y . Risk factors for the development of post-infectious bronchiolitis obliterans after Mycoplasma pneumoniae pneumonia in the era of increasing macrolide resistance. Respir Med. 2020; 175:106209. DOI: 10.1016/j.rmed.2020.106209. View

Marraro G, Luchetti M, Spada C, Galassini E, Giossi M, Piero A . Selective medicated (normal saline and exogenous surfactant) bronchoalveolar lavage in severe aspiration syndrome in children. Pediatr Crit Care Med. 2007; 8(5):476-81. DOI: 10.1097/01.PCC.0000282158.09783.7C. View

Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M . British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011; 66 Suppl 2:ii1-23. DOI: 10.1136/thoraxjnl-2011-200598. View

Tamiya S, Yoshikawa E, Ogura M, Kuroda E, Suzuki K, Yoshioka Y . Vaccination using inactivated Mycoplasma pneumoniae induces detrimental infiltration of neutrophils after subsequent infection in mice. Vaccine. 2020; 38(32):4979-4987. DOI: 10.1016/j.vaccine.2020.05.074. View

Chu C, Lei X, Li Y, Luo Y, Ding Y, Zhou W . High expression of miR-222-3p in children with Mycoplasma pneumoniae pneumonia. Ital J Pediatr. 2019; 45(1):163. PMC: 6916232. DOI: 10.1186/s13052-019-0750-7. View

Gise R, Elhusseiny A, Scelfo C, Mantagos I . Mycoplasma Pneumoniae-Induced Rash and Mucositis: A Longitudinal Perspective and Proposed Management Criteria. Am J Ophthalmol. 2020; 219:351-356. DOI: 10.1016/j.ajo.2020.06.010. View

10.

Miyashita N, Narita M, Tanaka T, Akaike H, Teranishi H, Oishi T . Histological findings in severe Mycoplasma pneumoniae pneumonia. J Med Microbiol. 2017; 66(5):690-692. DOI: 10.1099/jmm.0.000501. View

11.

Tan X, Wu S, Zhang J, Li X, Gao P, Wang Y . [Clinical efficacy of porcine pulmonary surfactant combined with budesonide suspension intratracheal instillation in the treatment of neonatal meconium aspiration syndrome]. Zhongguo Dang Dai Er Ke Za Zhi. 2016; 18(12):1237-1241. PMC: 7403089. View

12.

Yang C, Jeng M, Soong W, Lee Y, Tsao P, Tang R . Acute pathophysiological effects of intratracheal instillation of budesonide and exogenous surfactant in a neonatal surfactant-depleted piglet model. Pediatr Neonatol. 2010; 51(4):219-226. DOI: 10.1016/S1875-9572(10)60042-3. View

13.

Rokkas T, Niv Y, Malfertheiner P . A Network Meta-Analysis of Randomized Controlled Trials on the Treatment of Eosinophilic Esophagitis in Adults and Children. J Clin Gastroenterol. 2020; 55(5):400-410. DOI: 10.1097/MCG.0000000000001356. View

14.

Li G, Fan L, Wang Y, Huang L, Wang M, Zhu C . High co-expression of TNF-α and CARDS toxin is a good predictor for refractory Mycoplasma pneumoniae pneumonia. Mol Med. 2019; 25(1):38. PMC: 6688229. DOI: 10.1186/s10020-019-0105-2. View

15.

Su S, Li C, Zhao Y, Yu L, Wang Y, Wang Y . Outbreak of KPC-2-Producing ST76 Isolates in an Intensive Care Unit and Neurosurgery Unit. Microb Drug Resist. 2020; 26(9):1009-1018. DOI: 10.1089/mdr.2019.0363. View

16.

Alishlash A, Atkinson T, Schlappi C, Leal Jr S, Waites K, Xiao L . Carriage With De Novo Macrolide-Resistance and Breakthrough Pneumonia. Pediatrics. 2019; 144(4). DOI: 10.1542/peds.2019-1642. View

17.

Wang Z, Yang L, Ye J, Wang Y, Liu Y . Monocyte subsets study in children with Mycoplasma pneumoniae pneumonia. Immunol Res. 2019; 67(4-5):373-381. DOI: 10.1007/s12026-019-09096-6. View

18.

Israel S, Kumar A, DeAngelis K, Aurivillius M, Dorinsky P, Roche N . Pulmonary deposition of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects. Eur J Pharm Sci. 2020; 153:105472. DOI: 10.1016/j.ejps.2020.105472. View

19.

Wang L, Chen S, Huang Y, Qin F, Ou W, Liu H . [Application of flexible bronchoscopy in children with respiratory diseases]. Zhongguo Dang Dai Er Ke Za Zhi. 2017; 19(11):1174-1179. PMC: 7389317. View

20.

Li B, Han S, Liu F, Kang L, Xv C . Budesonide Nebulization in the Treatment of Neonatal Ventilator Associated Pneumonia. Pak J Med Sci. 2017; 33(4):997-1001. PMC: 5648980. DOI: 10.12669/pjms.334.12907. View